HTRA1 and pancreatitis: After a series of in vitro and in vivo experiments, we have finally confirmed that carfilzomib significantly inhibited the malignant phenotype of PDAC cells, and the progression of pancreatitis-initiated PDAC by suppressing HTRA1, which is promising to sever as an emerging targeted drug for PDAC therapy.